Hilaryano Ferreira’s Post

Effects of α-synuclein pathology in normal aging and Alzheimer’s disease A study using a cerebrospinal fluid (CSF) seed amplification assay (SAA) investigated the presence of pathological α-synuclein, a key biomarker for Lewy body disease (LBD), in clinically unimpaired (CU) individuals and those with Alzheimer's disease (AD). The results showed α-synuclein positivity in 9% of CU, 14% of mild cognitive impairment (MCI), and 19% of AD dementia participants, significantly lower than the 81% seen in a dedicated LBD cohort. Within the CU group, those who were α-synuclein positive were older and showed poorer performance in executive function and working memory, along with more self-reported LBD-related non-motor symptoms. Interestingly, α-synuclein status in CU participants wasn't linked to AD biomarkers (amyloid or tau), memory performance, or motor symptoms. The study, available as a Preprint https://lnkd.in/eSudBkPj concludes that the CSF SAA test for α-synuclein can independently predict subtle cognitive changes and early clinical symptoms in aging adults, adding to the understanding of α-synuclein's role in clinically healthy and AD-affected populations. #genetics #genomics #precisionmedicine #genomicmedicine #brain #neurology #neuroscience #neurodegeneration #neuroinflammation #inflammation #immunity #metabolism #aging #longevity #cognition #dementia #alzheimer #parkinson #raredisease #gerosciene #biomarkers #therapeutics #biotechnology #innovation #research #clinicalresearch #science #sciencecommunication

⚡️ New publication! 🧪 European Heart Journal – Cardiovascular Pharmacotherapy 👉 “Interdisciplinary recommendations for recurrent hyperkalaemia: insights from the GUARDIAN-HK European Steering Committee” 🔑 Key points: ✔️ HK = high potassium in blood, linked to ↑ risk in CKD, HF & CV disease ✔️ Early detection + prevention are essential ✔️ Need for a multidisciplinary, coordinated approach 👩⚕️👨⚕️ ✔️ New recommendations to guide clinicians across Europe 🌍 🔗 Read more: https://lnkd.in/dyYkTKpu #Cardiology #Nephrology #Hyperkalaemia #MedicalResearch #ESC INCLIVA Instituto de Investigación Sanitaria https://lnkd.in/dCQwVqD5

Porphyromonas gingivalis, a bacterium linked to gum disease, may play a significant role in Alzheimer's disease by entering the bloodstream, reaching the brain, and triggering inflammatory and neurodegenerative processes. This bacterium produces toxic proteases called gingipains, which can damage brain cells and contribute to neuroinflammation, amyloid plaque formation, and tau pathology. Studies have found P. gingivalis in the brains of Alzheimer's patients, and its presence is associated with increased risk of cognitive decline. Research suggests that gingipain inhibitors may be a potential therapeutic target to prevent or slow disease progression. The connection between P. gingivalis and Alzheimer's highlights the importance of oral health in overall brain health, and further research is needed to understand the mechanisms and potential treatments. We are about to release our upcoming issue and we are open for new submissions and you can submit yours here: clinicalpractice@genesispub.org #AlzheimersDisease #PorphyromonasGingivalis #GumDisease #Neurodegeneration #Neuroinflammation #BrainHealth #NeurologicalDisorders #MedicalResearch #HealthcareInnovation

September is World Alzheimer's Month. This month, Genomadix is joining the global community in highlighting the urgent need for advancements in Alzheimer's disease (AD) diagnosis and treatment. The shift toward a precision medicine approach is vital for optimizing patient care and outcomes. With the rise of new innovative therapies, FDA guidelines encourages ApoE genotyping prior to initiating anti-amyloid therapy to assess the risk of amyloid-related imaging abnormalities and ensure patient safety and providing optimal treatments. (1) At Genomadix, we truly believe that bringing rapid molecular diagnostics to the forefront is revolutionary for personalized medicine. 1. FDA. (2023). FDA Convets Novel Alzheimer’s Disease Treatment to Traditional Approval. https://lnkd.in/d6-Cjzxe. Accessed September 9, 2025. #WorldAlzheimersMonth #Alzheimers #PrecisionMedicine #WHO #MolecularDiagnostics #GeneticTesting #EarlyDetection #Biomarkers #Neurology #HealthTech #Genomadix #GenomadixCube #biotechnology #diagnostics #molecualrdiagnostics #genotyping #genetictesting #healthcare #precisionmedicine #precisionhealth #pharmacogenetics #PGx #pgxmovement #Innovation #Networking #Cardiology #Neurology #Stroke #Cardio #Health #HeartDisease #optimizedDAPT #DAPT #AntiplateletTherapy #ticagrelor #prasugrel #P2Y12 #PCI #ACS #Future #healthtalk #HealthInnovation #RapidCYP2C19 #CYP2C19 #FastCYP2C19 #GenomadixCYP2C19 #RapidTesting

High levels of cognitive impairment and p-tau217 have been found in a vascular patient cohort. A recent study of 162 community-dwelling patients with vascular disease found that 55% had elevated plasma p-tau217, a key #Alzheimer’s #biomarker — despite no prior #dementia diagnoses. Using Simoa®'s ultra-sensitive assays, researchers identified early AD pathology with high accuracy, revealing a critical opportunity for brain health screening in cardiovascular care. Learn more: https://lnkd.in/e5UR7yFP

"Deep white-matter hyperintensities (DWMH) on brain magnetic resonance imaging were significantly more prevalent and more extensive among individuals with systemic sclerosis (SSc) vs matched healthy controls, pointing to possible cerebral small-vessel disease among this patient population, according to study results published in Rheumatology." Read more about "Brain MRI Study Uncovers Potential Small-Vessel Disease Burden in SSc" #brainmri #smallvesseldisease #yourhealthmatters https://lnkd.in/ggwayYpU

Excited to share our recent study in CJASN showing females with kidney failure and acute coronary syndrome having lower rates of revascularization strategies than males. https://lnkd.in/g3ehNGPM ❤️ Coronary artery disease is the leading cause of death in patients with end-stage kidney disease (ESKD), yet little is known about treatment and outcomes in females and males • 📊 Using the United States Renal Data System, we studied 59,951 dialysis patients (2005–2018) with acute coronary syndrome (ACS). • 🧑⚕️ We compared rates of coronary revascularization (PCI, CABG, or both) and subsequent all-cause mortality between males and females. • 🚨 Key finding: Females were less likely than males to receive PCI (14% lower), CABG (42% lower), or both procedures (41% lower). • 📉 Mortality outcomes: Females had a slightly lower risk of death without treatment and after PCI, but no survival difference after CABG. • 🔎 Next step: Understanding the reasons behind females receiving leaser revascularization procedures can help guide future research and inform clinical decision-making to improve care. Charuhas Thakar Annette Christianson @anthony leonard Pragati Basera Deidra Crews, MD, ScM, FASN, MACP Jack Rubinstein Daniel Schauer Mark Mitsnefes #Cardiology #Nephrology #Dialysis #AcuteCoronarySyndrome #Outcomes

💡 Did you know? Kidney diseases significantly increase the risk of complications and mortality from other chronic conditions and infections. Since 2022, the ISN Cardio-Kidney-Metabolic (CKM) initiative has brought together nephrologists and cardiologists from ISN-ASPC, Kodigo, and RPA to strengthen collaboration across specialties. 🧰 One key outcome: the SGLT2i Toolkit — a practical, focused resource for healthcare professionals managing patients with cardio-kidney-metabolic complications. 👉 Explore the toolkit and put it into practice: https://lnkd.in/eyTNuyAh #KidneyHealth #Cardiology #Nephrology #CKM #SGLT2i #ISNGlobal

✨ Professor Michael Decker (Julius Maximilian University of Würzburg) visited LIOS and delivered a lecture on “Neuroprotective Hybrid Molecules and Photopharmacology of Cannabinoid Receptor 2 Ligands.” His team develops hybrid molecules with dual action — slowing brain cell degeneration by inhibiting BChE while activating the CB₂ receptor to reduce inflammation and boost brain protection 💊. In Alzheimer’s model mice, these molecules protect against memory loss. Another focus is photopharmacology 💡 — using light to activate drugs directly in the brain, avoiding unwanted effects elsewhere. This marks a promising new direction in neurodegenerative disease treatment, though new-generation drugs will take time ⏳ to develop. Professor Decker stressed that Alzheimer’s is severe, but early treatment is crucial to slow progression and protect brain health. #JuliusMaximiliansUniversitätWürzburg #NeuroprotectiveMolecules #Photopharmacology #AlzheimersResearch #LIOS #Neurodegeneration #COSTaction #SIGMA1EUROPE

Exploring the multifaceted role of extracellular vesicles in Alzheimer's disease: in this review article, Anna R. R. Da Conceicao, Fernanda De Felice at Federal University of Rio de Janeiro and collaborators summarized the diverse roles of extracellular vesicles in Alzheimer’s disease (AD), highlighting both their neuroprotective functions and their contribution to disease progression. EVs, released by various cell types, mediate intercellular communication under both normal and pathological conditions. In AD, EVs transported neuroinflammatory factors, pathogenic amyloid-β, and phosphorylated tau into recipient neurons, promoting pathology and neuronal degeneration. At the same time, EVs supported physiological processes, such as synaptic plasticity, neuronal activity, and tissue homeostasis in the central nervous system 🔗 https://lnkd.in/emXmFZrV Notably, EVs carrying neurotoxic molecules were able to cross the blood–brain barrier, making them promising biomarkers for minimally invasive AD diagnostics. They also engaged neuroprotective pathways and facilitated periphery-to-brain signaling, with alterations in EV content proposed as potential therapeutic strategies. Despite challenges such as standardization of isolation methods and limited knowledge of EV biodistribution, the use of EVs as diagnostic and therapeutic tools was presented as a rapidly advancing and promising field in AD research. An article co-authored by Júlia Marinatto, Lisandra Pinheiro and Tayná Rody. #extracellularvesicles #exosomes #Alzheimersdisease #biomarkers #Vesiculab